All Oncology News

The combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with obinutuzumab/chlorambucil in patients with previously untreated chronic lymphocytic leukemia, meeting the primary endpoint of the phase III ELEVATE-TN trial.

Ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.

Carlos Manuel de Castro III, MD, highlights current treatment approaches for severe aplastic anemia and some of the unmet needs that still exist.

Henry T. Lynch, MD, the Charles F. and Mary C. Heider Endowed Chair in Cancer Research at Creighton University and a 2019 Giants of Cancer Care® award winner known by many as the “father of cancer genetics,” died June 2 at the age of 91.

The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Harry P. Erba, MD, PhD, provides insight into how to navigate through the targeted therapies available in the treatment of acute myeloid leukemia and discussed the work that lies ahead in this space.

The FDA has accepted a biologics license application for the investigational erythroid maturation agent luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, as well as for adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.

Matthew S. McKinney, MD, discusses exciting treatment advances made in Hodgkin and non-Hodgkin lymphoma, specifically the compelling research in follicular lymphoma and mantle cell lymphoma.

The FDA has granted a priority review designation to a supplemental biologics license application for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Cristina Gasparetto, MD, discusses the rapidly evolving field of relapsed/refractory myeloma.

Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.

A new drug application has been submitted to the FDA for tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

COTA, Inc., a leading precision medicine technology company, has signed a 2-year Research Collaboration Agreement with the FDA’s Information Exchange and Data Transformation program.

The FDA has granted copanlisib (Aliqopa) a breakthrough therapy designation for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

Corey J. Langer, MD, highlights how precision medicine has emerged in the treatment of patients with non–small cell lung cancer via targeted therapies and checkpoint inhibitors.

The FDA approved a supplemental new drug application to update the label for gilteritinib to include final analysis data from the phase III ADMIRAL trial, which demonstrated an improvement in overall survival with the FLT3 inhibitor compared with salvage chemotherapy in adult patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

The FDA has granted a fast track designation to ARV-110, a PROTAC® protein degrader, for use as a treatment of patients with metastatic castration-resistant prostate cancer who have disease progression following ≥2 systemic therapies.

Raajit K. Rampal, MD, PhD, discusses a retrospective analysis of pre-transplant samples from patients with myelofibrosis to determine the value of mutational profiling in predicting outcomes after transplant.

The FDA has granted a fast track designation to lasofoxifene for use as a treatment of female patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who harbor ESR1 mutations.

Banu Arun, MD, discusses how the role of genetic testing is evolving in breast cancer with the development of new targeted agents.

The European Medicines Agency has validated and accepted a marketing authorization application for the trastuzumab biosimilar HD201 (Tuznue), according to the developer Prestige BioPharma.

The FDA has approved the R2 regimen of lenalidomide plus rituximab for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

Gary D. Steinberg, MD, a nationally recognized specialist in the surgical management of bladder cancer, has been named director of the Goldstein Urology Bladder Cancer Program at NYU Langone Health.

Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.

The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

The FDA has approved ruxolitinib for the treatment of adult and pediatric patients ≥12 years of age with steroid-refractory acute graft-versus-host disease.

Mark M. Zalupski, MD, sheds light on the current treatment landscape of advanced gastric cancer and the numerous challenges that remain.

The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy.

Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.